- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03493581
Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR-BioMarkers (BM) Profiling) (PIONeeR)
PIONeeR study is a prospective, multicenter study without administration of an investigational product.
The promotion and funding will be done by the Assistance Publique Hôpitaux de Marseille (APHM), the coordination by AMU. There will be 3 principal investigational clinical centres in France:
- Service d'Oncologie Multidisciplinaire et Innovations Thérapeutiques in APHM, Marseille, supervised by Prof. L. Greillier
- Medical Oncology Department of Centre Léon Bérard, Lyon, supervised by Prof. M. Pérol
- Unité d'Oncologie Thoracique, CHU Larrey /Oncopôle, Toulouse, supervised by Prof. J. Mazières.
Some secondary centres, nearby the three principal mentioned above, will be associated to ensure recruitment of patients, in accordance to provisional planning.
- The primary objective is to validate the existence and distribution of the hypothetical immune profile (within blood and tumoral tissue) explaining primary or adaptive resistance to standard PD-1 inhibitors monotherapy, in NSCLC patients.
The secondary objectives are to better characterize :
- PK/PD relationships,
- inter-patient PK variability,
- If systemic exposure levels could be predictive of efficacy of PD-1 ICI, in NSCLC patients.
Some exploratory objectives are :
- to assess a predictive value of a panel of endothelial biomarkers, in NSCLC patients.
- to compare predictive immune & endothelial biomarker profiles with those of sensitive tumors.
- to better understand which profiles track significantly with progression following PD-1 ICI administration, in order to improve advanced NSCLC patients' stratification, for future clinical trials.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Visits will match with usual schedule of patient's appointments with their referent oncologist or for injections of ICIs, when blood sampling or biopsies will be done. Feces will be collected by patients themselves, at home (optional).
The same day of registration for either an EMA approved first line PD-1 or PD-L1 inhibitor in combination with platinum-based chemotherapy OR a standard 2nd or 3rd line PD-(L) 1 ICIs monotherapy (to date, Nivolumab, Pembrolizumab, Atezolizumab), 450 advanced NSCLC patients will undergo a screening visit (Vs). If they are eligible, after signing an informed written consent, they will be blood-sampled specifically for the study:
- after 3 or 4 weeks (V1-1st assessment of PK/PD, after the 2d course),
- after 6 weeks (V2),
- after 8 or 9 weeks (V3-2nd assessment of PK/PD, after the last course),
- after 12 weeks of treatment (V4- samples for 3rd assessment of PK/PD and other analyses ).
- after 18 weeks (V5- samples for 4th assessment of PK/PD and other analyses,),
- after 24 weeks of treatment (V6-5th assessment of PK/PD and other analyses).
Patients will also be re-biopsied (primitive tumor or metastasis) specifically for the study, at V2. Referent patients'oncologist will opt for the simplest technical approach with a minimal risk exposure for patients. Standard procedures will be implemented for subsequent patient's monitoring.
Patients will also provide remaining samples from pre-treatment surgical resections/biopsies (primitive tumor or metastasis).
If they are amenable to collect feces samples at home, an auto collection kit will be supplied to them, before the first injection (Vs) and when they come for the 2nd course (i.e after 3 or 4 weeks post initiation) in order to self-collect feces within the week beforeV2 - 6 weeks post initiation).
Following the last study visit (V4 or V5 or V6)or at the time of a subsequent disease progression, patients will enter to the follow up period (a minimum 24 weeks ). They will be followed by their usual referent oncologist, no additional visit is required. Subsequent response to the anti-PD (L) 1 treatment, anti-cancer therapy, survival will be collected via patient medical records and analysed for current study.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: FABRICE BARLESI
- Phone Number: +33 (0)4 91 38 56 28
- Email: fabrice.barlesi@ap-hm.fr
Study Locations
-
-
-
Marseille, France, 13354
- Assistance Pubique Hopitaux de Marseille
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- - Patients must be over 18 years
- Patients must have histologically confirmed diagnosis of advanced (proven stade IV) or recurrent NSCLC,
- Their ECOG Performance Status must be of 0 or 1
- EITHER patients must be previously untreated and eligible for an EMA approved first line PD-1 or PD-L1 inhibitor in combination with platinum-based chemotherapy, irrespective of their tumor histology
- These EMA approved first line combinations must be reimbursed by French Health Insurance or at least, must have an Authorization for Temporary Use (ATU) in France
- OR Patients must display disease progression after at least one line of platinum-based chemotherapy and eligible for a registered second or third line PD-1 or PD-L1 inhibitor in monotherapy (to date, Nivolumab, Pembrolizumab, Atezolizumab)
- For patients registered for a 2nd or 3rd line, those with known actionable molecular alteration (EGFR activating mutation, ALK rearrangement, ROS1 rearrangement) should have received a specific inhibitor
- Patients must have an available archived tissue from a standard tumor biopsy for PD-L1 assessment, done before PD-1 ICI initiation
- Patients must have an available archived tissue from a standard tumor biopsy for PD-L1 assessment, done before PD-1 ICI initiation
- Patients must have adequate organ functions
- Patients must have provided a signed and dated, written informed consent prior to any study specific procedures, sampling and analyses
Exclusion Criteria:
- Patients previously untreated and eligible for a first line PD-1 or PD-L1 inhibitor in monotherapy
- Combination of PD-1 or PD-L1 inhibitor with bevacizumab
- Exclusive bone progression
- Exclusive cerebral progression not amenable to surgical biopsy
- Absence of a target lesion according to RECIST criteria 1.1
- Life expectancy of less than 3 months
- Severe adverse events from PD-1 treatment
- Abnormal coagulation contraindicating biopsy
- History of hemorrhagic or thrombotic stroke, TIA or other CNS bleeds
- Active uncontrolled or serious infection (viral, bacterial or fungal)
- Active infection including VHB and VHC infections
- Individuals deprived of liberty or placed under the authority of a tutor
- Patient unable to understand, read and/or sign an informed consent
- Any condition which in the Investigator's opinion would jeopardize compliance with the protocol of the study
- Patients without Health insurance scheme or Universal Medical Coverage (CMU) or any equivalent scheme
- Pregnant or breast-feeding women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NSCLC patients
|
re-biopsy (primitive tumor or metastasis) specifically for the study, at V2(6 weeks)
If they are amenable to collect feces samples at home, an auto collection kit will be supplied to them, before the first injection (Vs) and when they come for the 2nd course (i.e after 3 or 4 weeks post initiation) in order to self-collect feces within the week beforeV2 - 6 weeks post initiation).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immuno-monitoring
Time Frame: 54 MONTHS
|
BLOOD SAMPLES to characterize B, T, NK, and dendritic cell subsets and monocyte populations as well as Innate Lymphoid Cells (ILC) with cytometry analysis
|
54 MONTHS
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure the number of somatic mutations
Time Frame: 54 MONTHS
|
BLOOD SAMPLES- extraction of nucleic acids from Plasma
|
54 MONTHS
|
Measure the number of somatic mutations
Time Frame: 54 MONTHS
|
Tumor tissues- extraction of nucleic acids
|
54 MONTHS
|
measure the Circulating endothelial cells (CECs)
Time Frame: 54 MONTHS
|
BLOOD SAMPLES using a CD146-based immunomagnetic separation assay.
|
54 MONTHS
|
Minimum Plasma Concentration Cmin of anti PD (L) 1 treatment
Time Frame: 54 MONTHS
|
BLOOD SAMPLES
|
54 MONTHS
|
Maximum Plasma Concentration Cmax of anti PD (L) 1 treatment
Time Frame: 54 MONTHS
|
BLOOD SAMPLES
|
54 MONTHS
|
lymphocytes DNA extraction's
Time Frame: 54 MONTHS
|
Relevant polymorphisms will be screened by NGS technology
|
54 MONTHS
|
Collaborators and Investigators
Investigators
- Study Director: François CREMIEUX, ASSISTANCE PUBLIQUE HOPITAUX D EMARSEILLE
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017-67
- 2018-A03518-45 (Other Identifier: IDRCB)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Cancer Patients
-
BIND TherapeuticsCompletedSquamous Cell Non-small Cell Lung Cancer | KRAS Positive Patients With Non-small Cell Lung CancerUnited States, Russian Federation
-
Marc de PerrotOzmosis Research Inc.Not yet recruitingNon-small Cell Lung Cancer (NSCLC) | Lung Cancer Patients
-
Fondazione Ricerca TraslazionaleNot yet recruitingNon-small-cell Lung Cancer PatientsItaly
-
University of Turin, ItalyUnknownNon Small Cell Lung Cancer PatientsItaly
-
Fondazione Ricerca TraslazionaleRecruiting
-
Second Affiliated Hospital of Xi'an Jiaotong UniversityXijing Hospital; First Affiliated Hospital Xi'an Jiaotong University; Shanxi... and other collaboratorsUnknownPatients With Non-small Cell Lung CancerChina
-
AstraZenecaCompletedEGFR Mutated Non-small Cell Lung Cancer PatientsSpain
-
University of AarhusCompletedNon-small Cell Lung Cancer PatientsDenmark
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
Shanghai Chest HospitalNot yet recruitingCardiac Event | Immune Checkpoint Inhibitor | Adverse Reactions | Non-Small Cell Lung Cancer Patients
Clinical Trials on BIOPSY
-
UNICANCERNational Cancer Institute, FranceActive, not recruitingTriple-Negative Breast NeoplasmFrance
-
Chandan SenTerminatedWound Leg | Non-Diabetic Patients | Chronic Ulcer Leg/FootUnited States
-
Duke UniversityCompletedInterstitial Lung DiseaseUnited States
-
Postgraduate Institute of Medical Education and...CompletedLung Cancer | Endobronchial GrowthIndia
-
Ardeshir RastinehadPhilips HealthcareRecruitingProstate Cancer | Prostate Disease | Elevated Prostate Specific Antigen | Family History of Prostate Cancer | Positive Digital Rectal ExamUnited States
-
Centre Hospitalier Universitaire de NiceUnknownParodontitis Aggressive | Parodontitis ChronicFrance
-
Shandong Cancer Hospital and InstituteUnknownBreast Cancer | Sentinel Lymph NodeChina
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnCastration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer
-
Johns Hopkins UniversityCompleted
-
Odense University HospitalNot yet recruitingProstate Cancer (Diagnosis)